CHRS – Coherus BioSciences, Inc.
Coherus BioSciences, Inc.
CHRS
$1.04Name : Coherus BioSciences, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $119,817,352.00
EPSttm : -0.38
Coherus BioSciences, Inc.
$1.04
0.00%
$0.0000
Fair Value
Margin Of Safety %
Put/Call OI Ratio
0.05
Float Short %
22.69
EPS 1 Diff
0.13
EPS Year Diff
1.83
Ticker: CHRS
21 items
«
‹
of 1
›
»
Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
---|---|---|---|---|---|
2024-09-06 | CHRS | 1.24 | 0.11 | 0.00 | 12976 |
2024-09-09 | CHRS | 1.305 | 0.11 | 0.13 | 13078 |
2024-09-10 | CHRS | 1.365 | 0.11 | 0.00 | 13082 |
2024-09-11 | CHRS | 1.315 | 0.10 | 0.00 | 13153 |
2024-09-12 | CHRS | 1.28 | 0.10 | 0.00 | 13154 |
2024-09-13 | CHRS | 1.3 | 0.10 | 0.00 | 13159 |
2024-09-16 | CHRS | 1.03 | 0.10 | 0.48 | 13160 |
2024-09-17 | CHRS | 1.03 | 0.11 | 0.30 | 13529 |
2024-09-18 | CHRS | 1.06 | 0.11 | 0.01 | 13561 |
2024-09-19 | CHRS | 1.135 | 0.11 | 1.59 | 13557 |
2024-09-20 | CHRS | 1.025 | 0.10 | 0.25 | 13404 |
2024-09-23 | CHRS | 1.035 | 0.09 | 0.35 | 13145 |
2024-09-24 | CHRS | 1.01 | 0.09 | 0.07 | 13203 |
2024-09-25 | CHRS | 0.99 | 0.09 | 0.17 | 13317 |
2024-09-26 | CHRS | 1.065 | 0.09 | 3.60 | 13303 |
2024-09-27 | CHRS | 1.045 | 0.05 | 0.10 | 12993 |
2024-09-30 | CHRS | 1.045 | 0.05 | 1.46 | 12999 |
2024-10-01 | CHRS | 1.02 | 0.06 | 0.64 | 13173 |
2024-10-02 | CHRS | 1.025 | 0.06 | 0.00 | 13184 |
2024-10-03 | CHRS | 1.03 | 0.06 | 0.02 | 13206 |
2024-10-04 | CHRS | 1.045 | 0.05 | 0.01 | 14779 |
Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
21 items
«
‹
Current Page1 of 1
›
»
21 items
«
‹
of 1
›
»
Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
---|---|---|---|---|---|
2024-09-06 | CHRS | 1.24 | 70.4 | 50.3 | -0.97 |
2024-09-09 | CHRS | 1.30 | 70.4 | 53.8 | -0.97 |
2024-09-10 | CHRS | 1.36 | 70.4 | 53.7 | -0.97 |
2024-09-11 | CHRS | 1.32 | 70.4 | 51.2 | -0.97 |
2024-09-12 | CHRS | 1.29 | 70.4 | 51.2 | -0.97 |
2024-09-13 | CHRS | 1.30 | 70.4 | 52.5 | -0.97 |
2024-09-16 | CHRS | 1.04 | 70.4 | 45.3 | -0.97 |
2024-09-17 | CHRS | 1.04 | 70.4 | 51.8 | -0.97 |
2024-09-18 | CHRS | 1.06 | 70.4 | 52.7 | -0.97 |
2024-09-19 | CHRS | 1.14 | 70.4 | 54.7 | -0.97 |
2024-09-20 | CHRS | 1.02 | 70.4 | 49.1 | -0.99 |
2024-09-23 | CHRS | 1.03 | 70.4 | 52.6 | -0.99 |
2024-09-24 | CHRS | 1.00 | 70.4 | 51.1 | -0.99 |
2024-09-25 | CHRS | 0.99 | 70.4 | 52.0 | -0.99 |
2024-09-26 | CHRS | 1.06 | 66.7 | 54.4 | -0.99 |
2024-09-27 | CHRS | 1.05 | 66.7 | 51.7 | -0.70 |
2024-09-30 | CHRS | 1.04 | 66.7 | 51.9 | -0.70 |
2024-10-01 | CHRS | 1.02 | 66.7 | 51.2 | -0.70 |
2024-10-02 | CHRS | 1.02 | 66.7 | 52.3 | -0.70 |
2024-10-03 | CHRS | 1.03 | 66.7 | 52.5 | -0.70 |
2024-10-04 | CHRS | 1.05 | 66.7 | 52.5 | -0.70 |
Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
21 items
«
‹
Current Page1 of 1
›
»
21 items
«
‹
of 1
›
»
Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
---|---|---|---|---|
2024-09-06 | CHRS | 0.00 | -1.46 | 21.71 |
2024-09-09 | CHRS | 0.00 | -1.48 | 21.71 |
2024-09-10 | CHRS | 0.00 | -1.48 | 21.71 |
2024-09-11 | CHRS | 0.00 | -1.48 | 21.71 |
2024-09-12 | CHRS | 0.00 | -1.48 | 22.74 |
2024-09-13 | CHRS | 0.00 | -1.48 | 22.74 |
2024-09-16 | CHRS | 0.00 | -1.48 | 22.74 |
2024-09-17 | CHRS | 0.00 | -1.48 | 22.74 |
2024-09-18 | CHRS | 0.00 | -1.48 | 22.74 |
2024-09-19 | CHRS | 0.00 | -1.48 | 22.74 |
2024-09-20 | CHRS | 0.00 | -1.48 | 22.74 |
2024-09-23 | CHRS | 0.00 | -1.48 | 22.74 |
2024-09-24 | CHRS | 0.00 | -1.48 | 22.74 |
2024-09-25 | CHRS | 0.00 | -1.48 | 22.69 |
2024-09-26 | CHRS | 0.00 | -1.48 | 22.69 |
2024-09-27 | CHRS | 0.00 | -1.48 | 22.69 |
2024-09-30 | CHRS | 0.00 | -1.48 | 22.69 |
2024-10-01 | CHRS | 0.00 | -1.48 | 22.69 |
2024-10-02 | CHRS | 0.00 | -1.48 | 22.69 |
2024-10-03 | CHRS | 0.00 | -1.48 | 22.69 |
2024-10-04 | CHRS | 0.00 | -1.48 | 22.69 |
Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
21 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
-0.2
Avg. EPS Est. Current Quarter
-0.09
Avg. EPS Est. Next Quarter
-0.07
Insider Transactions
Institutional Transactions
-1.48
Beta
0.65
Average Sales Estimate Current Quarter
62
Average Sales Estimate Next Quarter
61
Fair Value (Academic)
Quality Score
45
Growth Score
51
Sentiment Score
74
Actual DrawDown %
95.4
Max Drawdown 5-Year %
-95.6
Target Price
7.25
P/E
Forward P/E
PEG
P/S
0.39
P/B
P/Free Cash Flow
EPS
-0.41
Average EPS Est. Cur. Y
-0.7
EPS Next Y. (Est.)
-0.23
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-9.52
Relative Volume
1.44
Return on Equity vs Sector %
13.3
Return on Equity vs Industry %
-7.9
EPS 1 7Days Diff
0.3
EPS 1 30Days Diff
0.49
EBIT Estimation
52.5
Coherus BioSciences, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 246
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
stock quote shares CHRS – Coherus BioSciences, Inc. Stock Price stock today
news today CHRS – Coherus BioSciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CHRS – Coherus BioSciences, Inc. yahoo finance google finance
stock history CHRS – Coherus BioSciences, Inc. invest stock market
stock prices CHRS premarket after hours
ticker CHRS fair value insiders trading